



The Synthetic Gene Therapy Company

## Eukarÿs announces the finalization of the 3<sup>rd</sup> generation of its C3P3 expression system

Evry, January 15, 2019,

Eukarÿs announces the development of the third generation of its proprietary C3P3 expression system (C3P3-G3), the first artificial technology to produce high-yield messenger RNA and thus proteins of interest in cells or living eukaryotic organisms. This third generation, developed entirely by synthetic biology, required more than a year of development. It increases the performance of the C3P3 system with expression levels 5 times greater than transient expression vectors in cultured human cells.

Philippe Jais, Chairman and CSO of Eukarÿs said: "The C3P3 system is a powerful transcriptional engine of great complexity whose improvement is a continuous process. We welcome the development of this new generation of the better performing C3P3 system that will be implemented in all of our synthetic gene therapy products - EUK-LPR, then others in preparation - as well as our cellular tools for the bioproduction of recombinant proteins and viruses".

### About Eukarÿs

Eukarÿs is a French privately-owned biotechnology company of the Genopole biocluster. Using its C3P3 expression system, Eukarÿs is developing a new approach to non-viral synthetic gene therapy that is efficient, safe, well tolerated, inexpensive and usable for the treatment of most monogenic or multifactorial human diseases. The C3P3 system is also used for the development of powerful tools for the bioproduction of recombinant proteins and viruses.

**Contact:** Eukarÿs SAS | Genopole Campus 3 | 4 rue Pierre Fontaine | 91058 Evry Cedex, France | [contact@eukarys.com](mailto:contact@eukarys.com) | [www.eukarys.com](http://www.eukarys.com)